19.65
price down icon2.04%   -0.41
after-market Handel nachbörslich: 19.65
loading
Schlusskurs vom Vortag:
$20.06
Offen:
$19.89
24-Stunden-Volumen:
884.48K
Relative Volume:
2.16
Marktkapitalisierung:
$1.06B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-85.21M
KGV:
-10.40
EPS:
-1.89
Netto-Cashflow:
$-68.53M
1W Leistung:
-7.14%
1M Leistung:
+10.58%
6M Leistung:
-12.67%
1J Leistung:
-13.44%
1-Tages-Spanne:
Value
$19.22
$20.09
1-Wochen-Bereich:
Value
$19.22
$21.89
52-Wochen-Spanne:
Value
$13.30
$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name
Firmenname
Enliven Therapeutics Inc
Name
Telefon
720-647-8519
Name
Adresse
6200 LOOKOUT ROAD, BOULDER
Name
Mitarbeiter
65
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ELVN's Discussions on Twitter

Vergleichen Sie ELVN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ELVN
Enliven Therapeutics Inc
19.65 1.06B 0 -85.21M -68.53M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-16 Eingeleitet Goldman Buy
2024-12-13 Eingeleitet BTIG Research Buy
2024-09-09 Eingeleitet H.C. Wainwright Buy
2024-06-11 Eingeleitet Robert W. Baird Outperform
2024-04-09 Eingeleitet Mizuho Buy
2023-03-29 Eingeleitet Jefferies Buy
Alle ansehen

Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten

pulisher
Jun 18, 2025

Enliven Therapeutics CEO Kintz sells $277k in shares By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 17, 2025

Enliven grosses $230M from stock sale - BizWest

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Eastern Progress

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data - MSN

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Raises $230m To Fund Scemblix Leukemia Challenger - insights.citeline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Given New $52.00 Price Target at Robert W. Baird - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group - Defense World

Jun 17, 2025
pulisher
Jun 17, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up on Analyst Upgrade - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey

Jun 16, 2025
pulisher
Jun 16, 2025

Enliven Therapeutics Closes Public Offering - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Biotech Enliven Therapeutics Secures Massive $230M Funding Through Oversubscribed Public Offering - Stock Titan

Jun 16, 2025
pulisher
Jun 16, 2025

Form 424B5 Enliven Therapeutics, - StreetInsider

Jun 16, 2025
pulisher
Jun 16, 2025

Enliven (ELVN) Gains Buy Rating from Goldman Sachs with $37 Price Target | ELVN Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 15, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Down – Should You Sell? - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Enliven (ELVN) Initiates $200M Public Stock Offering | ELVN Stoc - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - The Malaysian Reserve

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics prices $200 million public offering By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Inc (ELVN) Stock: A Year of Highs and Lows in the Market - investchronicle.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven to sell $200M in stock after positive drug trial - BizWest

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces $200 Mln Offering Of Common Stock, Pre-Funded Warrants - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics prices $200 million public offering - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

Biotech Breakthrough: Enliven Therapeutics Secures Massive $200M Funding Backed by Goldman Sachs - Stock Titan

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Public Offering Of $200 Mln Of Shares - Nasdaq

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Launches $200 Million Securities Offering - marketscreener.com

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Positive Phase 1 Trial Results - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics announces $200 million public offering - Investing.com

Jun 13, 2025
pulisher
Jun 13, 2025

SEC Form 424B5 filed by Enliven Therapeutics Inc. - Quantisnow

Jun 13, 2025
pulisher
Jun 13, 2025

Biotech Enliven Therapeutics Unveils Massive $200M Stock Offering with Pre-Funded Warrants Option - Stock Titan

Jun 13, 2025
pulisher
Jun 13, 2025

Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress - PR Newswire

Jun 13, 2025
pulisher
Jun 12, 2025

California State Teachers Retirement System Buys 1,940 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $984,000 Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Two Sigma Investments LP Has $329,000 Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Bank of America Corp DE Sells 14,504 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4% After Insider Selling - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Buys 26,449 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

ELVN Stock Price and Chart — NASDAQ:ELVN - TradingView

Jun 04, 2025
pulisher
Jun 03, 2025

Ameriprise Financial Inc. Invests $789,000 in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

What is Lifesci Capital’s Forecast for ELVN FY2025 Earnings? - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 01, 2025
pulisher
Jun 01, 2025

BNP Paribas Financial Markets Purchases New Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

What is Lifesci Capital’s Forecast for ELVN Q2 Earnings? - Defense World

May 31, 2025
pulisher
May 30, 2025

Enliven Therapeutics (ELVN) Gets a Buy from Mizuho Securities - The Globe and Mail

May 30, 2025
pulisher
May 30, 2025

Mizuho Adjusts Price Target on Enliven Therapeutics to $41 From $39, Maintains Outperform Rating - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World

May 30, 2025
pulisher
May 28, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stake Increased by Deutsche Bank AG - Defense World

May 28, 2025
pulisher
May 25, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.25 Consensus PT from Analysts - Defense World

May 25, 2025
pulisher
May 22, 2025

Enliven Therapeutics to Present at Upcoming Investor Conferences - Nasdaq

May 22, 2025
pulisher
May 22, 2025

(ELVN) Proactive Strategies - news.stocktradersdaily.com

May 22, 2025
pulisher
May 22, 2025

Enliven Therapeutics chief scientific officer sells $81,533 in stock - Investing.com Australia

May 22, 2025
pulisher
May 21, 2025

Enliven Therapeutics chief scientific officer sells $81,533 in stock By Investing.com - Investing.com India

May 21, 2025

Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Enliven Therapeutics Inc-Aktie (ELVN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
Jun 20 '25
Sale
21.40
12,500
267,458
965,188
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):